Cytomegalovirus: An Emerging Threat in Modern Medicine

A common member of the Herpesviridae family, cytomegalovirus (CMV), poses a serious threat to global public health, especially for immunocompromised people and newborns who are born infected. CMV is a double-stranded DNA virus that can periodically reactivate and develop lifelong latency. Geographics, age, socioeconomic status, and occupational exposure all have a substantial impact on seroprevalence; higher rates are seen in poorer nations, among healthcare professionals, and among those who look after young children. In immunocompromised hosts, CMV disease can present in various forms, including CMV retinitis, pneumonitis, hepatitis, colitis, and encephalitis. Solid organ and hematopoietic stem cell transplant recipients are at particular risk, with CMV contributing to graft rejection and increased mortality. Congenital CMV infection, which affects approximately 0.5–1% of live births, is the leading non-genetic cause of sensorineural hearing loss and neurodevelopmental disabilities in children. Maternal primary infection or reactivation during pregnancy can result in fatal infection, particularly if it occurs during the first trimester. Diagnosis of CMV infection relies on a combination of serological assays, molecular techniques, and histopathological examination. Antiviral therapy plays a crucial role in the management of CMV disease, particularly in high-risk populations. The development of letermovir, a newer antiviral with a unique mechanism targeting the viral terminase complex, offers an additional option for prophylaxis in hematopoietic stem cell transplant recipients. Cytomegalovirus remains a pervasive and clinically significant pathogen with diverse manifestations depending on host immunity. Advances in diagnostic techniques, antiviral therapy, and vaccine development have improved outcomes, yet significant challenges remain in controlling CMV-associated disease. Ongoing research into the molecular biology of CMV, host-pathogen interactions, and immune responses will be critical in informing future therapeutic and preventive strategies. A multifaceted approach that combines clinical vigilance, effective treatment protocols, public health education, and vaccine development holds the greatest promise for reducing the global burden of CMV infection. The review paper covers the virology, epidemiology, transmission mechanisms, and pathophysiology of CMV.